Repression of SMAD-dependent transforming growth factor-β signaling by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB

International Journal of Cancer

Volumn 105, Issue 5, 2003, Pages 661-668

  Mori, Naoki ^a   Morishita, Mariko ^b   Tsukazaki, Tomoo ^c   Yamamoto, Naoki ^d  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

^d TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Epstein Barr virus; LMP 1; NF B; Smad; TGF

Indexed keywords

COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; RNA; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA BINDING; DNA PROTEIN COMPLEX; ENZYME ASSAY; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS; VIRUS CELL TRANSFORMATION;

ANIMALS; BINDING, COMPETITIVE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, VIRAL; GENES, P16; GENES, REPORTER; HERPESVIRUS 4, HUMAN; HUMANS; I-KAPPA B PROTEINS; LIVER NEOPLASMS; LUNG; MINK; MODELS, GENETIC; NF-KAPPA B; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS; VIRAL MATRIX PROTEINS;

EID: 0038174743     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11146     Document Type: Article

References (51)

1. Rickison AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott-Raven Publishers, 1996. 2397-446.
2. Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincott-Raven Publishers, 1996. 2343-96.
3. Speck SH, Strominger JL. Transcription of Epstein-Barr virus in latently infected growth transformed lymphocytes. In: Klein G, ed. Advances in viral oncology. New York: Raven Press, 1989. 133-50.
4. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
5. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
6. Okan I, Wang Y, Chen F, Hu LF, Imreh S, Klein G, Wiman KG. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995;11:1027-31.
7. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP-1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 1992;267:24157-60.
8. Wang S, Rowe M, Lundgren E. Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-3.
9. Liebowitz D, Wang D, Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol 1986;58:233-7.
10. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996;93:11085-90.
11. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. Localization of the major NF-κB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 1997;272:19777-84.
12. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol 1997;71:4649-56.
13. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997;16:6478-85.
14. Eliopoulos AG, Gallagher NJ, Blake SMS, Dawson CW, Young LS. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-96.
15. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Roberts AB, Sporn MB, eds. Peptide growth factors and their receptors. Heidelberg: Springer-Verlag, 1990. 421-72.
16. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 1993;4:493-540.
17. Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R. Epstein-Barr virus mediates a switch in responsiveness to transforming growth factor, type β, in cells of the B cell lineage. Eur J Immunol 1987;17:299-301.
18. Janssen O, Gillis S, Kabelitz D. In vitro transformation by Epstein-Barr virus induces a switch in growth factor and anti-IgM responsiveness in a human leukemic B cell clone. Eur J Immunol 1990;20:7-14.
19. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharma S, Characterization of transforming growth factor-β1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncogene 1995;11:1615-22.
20. Arvanitakis L, Yaseen N, Sharma S. Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-β1-mediated growth inhibition in EBV-positive B cells. J Immunol 1995;155:1047-56.
21. Massague J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947-50.
22. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999;13:2105-24.
23. Wrana JL. TGF-β receptors and signaling mechanisms. Miner Electrolyte Metab 1998;24:120-30.
24. Topper JN, DiChiara MR, Brown JD, Williams AJ, Falb D, Collins T, Gimbrone MA Jr. CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor β transcriptional responses in endothelial cells. Proc Natl Acad Sci USA 1998;95:9506-11.
25. Janknecht R, Wells NJ, Hunter T. TGF-β-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev 1998;12:2114-9.
26. Feng X-H, Zhang Y, Wu R-Y, Derynck R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for Smad3 in TGF-β-induced transcriptional activation. Genes Dev 1998;12:2153-63.
27. Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 1998;273:22865-8.
28. Nishihara A, Hanai J, Okamoto N, Yanagisawa J, Kato S, Miyazono K, Kawabata M. Role of p300, a transcriptional coactivator, in signaling of TGF-β. Genes Cells 1998;3:613-23.
29. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein- Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
30. Floettmann JE, Rowe M. Epstein-Barr virus latent membrane protein-1 (LMP-1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerization for NF-κB activation. Oncogene 1997;15:1851-8.
31. Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY, Ballard DW. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol Cell Biol 1995;15:2809-18.
32. McKinsey TA, Brockman JA, Scherer DC, Al-Murrani SW, Green PL, Ballard DW. Inactivation of IκBβ by the Tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-κB. Mol Cell Biol 1996;16:2083-90.
33. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-7.
34. Li J-M, Nichols MA, Chandrasekharan S, Xiong Y, Wang X-F. Transforming growth factor β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site. J Biol Chem 1995;270:26750-3.
35. Suzuki T, Hirai H, Murakami T, Yoshida M. Tax protein of HTLV-1 destabilizes the complexes of NF-κB and IκB-α and induces nuclear translocation of NF-κB for transcriptional activation. Oncogene 1995;10:1199-207.
36. Mori N, Prager D. Transactivation of the interleukin-1α promoter by human T-cell leukemia virus type I and type II Tax proteins. Blood 1996;87:3410-7.
37. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 1997;389:85-9.
38. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier J-M. Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998;17:3091-100.
39. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
40. Goodman R, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000;14:1553-77.
41. Gerristen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997;94:2927-32.
42. Webster GA, Perkins ND. Transcriptional cross talk between NF-κB and p53. Mol Cell Biol 1999;19:3485-95.
43. Taipale J, Saharinen J, Keski-Oja J. Extracellular matrix-associated transforming growth factor-β: role in cancer cell growth and invasion. Adv Cancer Res 1998;75:87-134.
44. Alexandrow MG, Moses HL. Transforming growth factor β and cell cycle regulation. Cancer Res 1995;55:1452-7.
45. Yingling JM, Wang X-F, Bassing CH. Signaling by the transforming growth factor-β receptors. Biochim Biophys Acta 1995;1242:115-36.
46. Inman GJ, Allday MJ. Resistance to TGF-β1 correlates with a reduction of TGF-β type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 2000;81:1567-78.
47. Kenney JL, Guinness ME, Reiss M, Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int J Cancer 2001;91:89-98.
48. Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, Yazaki Y, Matsumoto K, Hirai H. The oncoprotein Evi-1 represses TGF-β signaling by inhibiting Smad3. Nature 1998;394:93-6.
49. Luo K, Stroschein SL, Wang W, Chen D, Martens E, Zhou S, Zhou Q. The Ski oncoprotein interacts with the Smad proteins to repress TGFβ signaling. Genes Dev 1999;13:2196-206.
50. Stroschein SL, Wang W, Zhou S, Zhou Q, Luo K. Negative feedback regulation of TGF-β signaling by the SnoN oncoprotein. Science 1999;286:771-4.
51. Nishihara A, Hanai J, Imamura T, Miyazono K, Kawabata M. E1A inhibits transforming growth factor-β signaling through binding to Smad proteins. J Biol Chem 1999;274:28716-23.